Summary of study ST001618

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001038. The data can be accessed directly via it's Project DOI: 10.21228/M8HX30 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data (Contains raw data)
Study IDST001618
Study TitleMetabolomics Analysis: Opioid Addiction Project (Golestan Cohort Study) - MS (part-I)
Study TypeUntargeted LC-MS Metabolomics Study
Study SummaryDrug addiction is a major threat to the public health in the US and many other countries. Opioid abuse is associated with increased risks for cancer, psychological complications, heart and lung disease, and infections of the liver and blood. Because metabolites are intrinsically involved in multiple metabolic pathways in vivo, the relative quantification of metabolites in body fluids (for example urine) can provide a profile of the metabolic state of an organism. Metabolomics is a powerful technique for revealing the impact of exposure on the overall biochemistry of an individual or system. Opioids can modify the output of urinary metabolites through many integrated neural and hormonal mechanisms within the periphery, central nervous system, and kidneys. Opioids modulate the expression of genes involved in neuroplasticity through epigenetic and possibly RNA modifications, ultimately change the intracellular signaling cascades and dysfunction, and cause long-lasting changes in metabolome. The objective of this study is to identify how opium impacts metabolic pathways to provide markers of abuse, long-term opium addiction, the addiction molecular pathway, and unknown metabolites that are important to differentiation of the study phenotypes. To reach these goals in the present study, the urine specimens of opium abusers and non-users as controls will be profiled using an untargeted liquid chromatography mass spectrometric (LC-MS/MS) at University of North Carolina at Chapel Hill. The Golestan Cohort Study is conducted in Northeast of Iran to primarily study the risk factors for upper gastrointestinal cancers in this high-risk region, in which about 50,000 volunteers were analyzed for opium users and their mortality. More than 8,000 of participants (17%) age 40-75 reported opium use with a mean duration of 12.7 years. Opium was either smoked or orally consumed. The participants were selected from the cohort stratified by opium use patterns and tobacco use.
Institute
University of North Carolina at Chapel Hill
DepartmentNutrition
Last NameSumner
First NameSusan
Address500 Laureate Way, Kannapolis, NC 28081
Emailsusan_sumner@unc.edu
Phone919-541-4456
Submit Date2020-12-01
Num Groups2
Total Subjects298
Raw Data AvailableYes
Raw Data File Type(s).raw
Analysis Type DetailLC-MS
Release Date2021-11-24
Release Version1
Susan Sumner Susan Sumner
https://dx.doi.org/10.21228/M8HX30
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Collection:

Collection ID:CO001688
Collection Summary:Non-fasted urine sample; spot urine.
Sample Type:Urine
Storage Conditions:-80℃
  logo